ADMA Biologics (ADMA) Earnings Date & Reports

Key Takeaways

• ADMA Biologics reported fourth-quarter 2025 revenue of $139.2 million, up 18% year over year, capping full-year revenue of $510.2 million, a 20% increase.
• Fourth-quarter adjusted net income grew 57% to $52.6 million, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 52% to $73.6 million.
• Flagship product ASCENIV generated $363 million in 2025 revenue, up 51% year over year, driving the company's growth.
• Management reiterated 2026 guidance, calling for revenue to exceed $635 million and adjusted EBITDA above $360 million.
• GAAP (Generally Accepted Accounting Principles) net income declined year over year largely because 2024 included an $84.3 million one-time tax benefit.

Earnings Context and Why It Matters

ADMA Biologics, a vertically integrated developer and manufacturer of plasma-derived therapies, has become one of the most closely watched commercial-stage biopharma names in the small-cap space. Its growth is anchored by ASCENIV, a specialty intravenous immune globulin (IVIG) product used to treat primary immunodeficiency. The fourth-quarter and full-year 2025 report matters because it tests whether the company can sustain its rapid revenue expansion while converting that growth into stronger margins and earnings power. With management guiding toward more than $1.1 billion in annual revenue by 2029, investors are focused on demand durability, payer coverage, and the successful transition of higher-yield manufacturing into routine production.

Reported Results

For the fourth quarter ended December 31, 2025, ADMA Biologics reported total revenue of $139.2 million, an 18% increase from $117.6 million a year earlier. Gross profit rose 40% to $88.8 million, producing a corporate gross margin of 63.8%, roughly a ten-percentage-point improvement year over year.

GAAP net income was $49.4 million, or $0.20 per diluted share, down from $111.9 million, or $0.46 per diluted share, in the prior-year quarter. The decline was primarily attributable to an $84.3 million non-cash, non-recurring income tax benefit recognized in 2024 related to a valuation allowance release. On an adjusted basis, net income rose 57% to $52.6 million, while adjusted EBITDA climbed 52% to $73.6 million.

For the full year, revenue reached $510.2 million, up 20%, with gross margin expanding to 57.4% from 51.5%. Full-year GAAP net income was $146.9 million, compared with $197.7 million in 2024, again reflecting the prior-year tax benefit. Adjusted net income grew 35% to $160.8 million, and adjusted EBITDA increased 40% to $231.0 million.

AI Screener

Investors tracking fast-moving healthcare and biotech names can streamline their research using Tickeron's AI Screener. This AI-powered stock and ETF (exchange-traded fund) discovery tool helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to build a more data-driven watchlist.

Market Reaction and Investor Sentiment

Heading into the February 25, 2026 report, sentiment was already positive after management pre-announced strong preliminary full-year revenue in January and issued upside guidance on its November 2025 call. The record fourth-quarter results largely validated that optimism, reinforcing the view that ASCENIV remains early in its market-penetration curve. Investors appeared to focus on the quality of the beat: expanding gross margins, accelerating adjusted profitability, and reiterated long-term targets. Key watchpoints that could sway sentiment include the pace of ASCENIV's mix shift versus the company's legacy BIVIGAM product, the closing of its plasma-center divestiture, and the transition to a new chief financial officer announced alongside results.

Forward Outlook and Key Factors to Monitor

Management's guidance calls for 2026 revenue to exceed $635 million, adjusted net income above $255 million, and adjusted EBITDA above $360 million. The company also reaffirmed longer-term targets of more than $775 million in 2027 revenue and more than $1.1 billion by 2029.

A central theme for 2026 is the first full year of yield-enhanced production, which management expects to support meaningful gross-margin expansion and rising earnings power. Investors should monitor FDA (Food and Drug Administration) lot releases and manufacturing execution, since sustained output is essential to meeting demand.

On the commercial side, watch ASCENIV utilization and payer coverage, as well as the expected shift toward a roughly 70/30 product mix favoring ASCENIV over BIVIGAM. The company's expanded distribution agreement with McKesson Specialty is intended to improve working capital efficiency and cash conversion.

Finally, watch balance-sheet and supply dynamics, including the pending close of the plasma-center divestiture and long-term access to more than 280 plasma collection centers. Together, these factors will shape whether ADMA can sustain its growth trajectory without sacrificing profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations